AzTrials
AzTrials

Obesity and OverweightNCT07012226

Comparison of Cardiometabolic Markers in Individuals With Hypertriglyceridemia With Low and High Weight Loss Responses to an Energy-restricted Diet

A study testing Low-calorie diet in people with Obesity and Overweight and Hypertriglyceridaemia, run by Shahid Beheshti University of Medical Sciences at 1 site in Iran.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Total RNA is extracted from isolated white blood cells, and cDNA is synthesized from these samples. Subsequently, the expression levels of the SIRT1 and leptin receptor genes are determined through quantitative PCR. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Obesity and Overweight, Hypertriglyceridaemia
What is being tested?
Low-calorie diet
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteIran
Study dates
10 Jun 2025to 27 Jan 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Mild to moderate hypertriglyceridemia (TG=150-500 mg/dL)
  • Body mass index (BMI) greater than 25
  • Not using fibrates

Who cannot join

  • Advanced chronic kidney disease patients
  • Patients with liver cirrhosis
  • Unwillingness to continue cooperating with the study
  • Any change in the treatment plan during the study, including changes in the type and dose of medications taken or the start of medications that affect blood lipids

Trial locations and contacts

1 site in 1 country.

Iran1 site
  • Nutrition Clinic located in the Faculty of Nutrition Sciences, Shahid Beheshti University of Medical Sciences

    Tehran, Tehran Province

Other trials in Iran

About this study

Official title: Effects of an Energy-restricted Diet on the Expression of the Sirtuin-1 and Leptin Receptor Genes in White Blood Cells, and Cardiometabolic Markers in Individuals With Hypertriglyceridemia: Comparison Between Low and High Weight Loss Responders

Total RNA is extracted from isolated white blood cells, and cDNA is synthesized from these samples. Subsequently, the expression levels of the SIRT1 and leptin receptor genes are determined through quantitative PCR.

Read the detailed description

Hypertriglyceridemia (HTG), defined as fasting triglycerides (TGs) ≥150 mg/dL, is a prevalent condition in the adult population, with an increasing prevalence that parallels the rise in obesity rates. There is a robust body of literature indicating a correlation between mild to moderate HTG and a number of complications, including cardiovascular disease and pancreatitis.

Lifestyle changes and weight loss could improve HTG. Dietary calorie restriction is a cornerstone in the weight loss program. However, the rate of achieving substantial weight loss through dietary interventions is often not high. Consequently, identifying factors associated with responders to both desirable and undesirable weight loss before initiating dietary interventions can help individuals struggling with weight loss. In this context, gene expression markers have been proposed as promising tools. For instance, a number of studies have identified predictors of body weight and improvement in glycemic status by comparing the transcriptomic profile of adipose tissue from obese and overweight individuals during a low-calorie diet. In other studies, peripheral blood cells have been utilized for the examination of gene expression profiles. Peripheral blood cells, including white blood cells, are readily available and, express most of the human genome. Consequently, they can reflect the gene expression of key tissues affecting energy homeostasis in response to nutritional changes or weight change. Sirtuin-1 (SIRT1) gene expression, a known regulator of glucose and lipid homeostasis, is altered by caloric restriction and weight loss. It is possible that the basal level of SIRT-1 expression may predict the metabolic response to weight loss. Conversely, leptin exerts influence over several physiological processes, including communication with the central nervous system, energy expenditure, and food intake. Obese individuals may exhibit higher levels of leptin resistance and reduced access to the central nervous system via the blood-brain barrier in comparison to lean individuals. The extent of leptin receptor expression may serve as a determining factor in these disparities. Consequently, the level of leptin receptor expression may also influence the response of individuals to a weight loss program.

The present study aims to evaluate the expression of SIRT-1 and leptin receptor genes in white blood cells and changes in cardiometabolic factors in individuals with hypertriglyceridemia associated with overweight and obesity. The variables will be compared at the beginning and end of the study between those who have lost less weight after two months and those who have lost more weight. The relationship of these variables to the percentage of weight loss will also be examined. The primary hypothesis posited that specific pre-weight loss factors could predict optimal weight loss responders. Secondary hypotheses were formulated with the objective of investigating how cardiometabolic markers would be affected by weight loss in response to a hypocaloric diet in subjects with HTG.

Methods:

The study population consists of people with mild to moderate hypertriglyceridemia who are overweight or obese and are placed on a low-calorie diet program.

Inclusion criteria:

  • Mild to moderate hypertriglyceridemia (TG=150-500 mg/dL)
  • Body mass index (BMI) greater than 25
  • Not using fibrates

Exclusion criteria:

  • Advanced chronic kidney disease patients
  • Patients with liver cirrhosis
  • Any change in the treatment plan during the study, including changes in the type and dose of medications taken or the start of medications that affect blood lipids.

All individuals deemed eligible will be placed on a low-calorie diet. The duration of the study is 2 months. To this end, the Mifflin formula is employed to calculate the requisite calories, with the level of physical activity factored into the calculation to determine the daily calorie requirement. Subsequently, 500 calories are deducted from this figure to derive a low-calorie diet. The determination of food groups is then based on their respective caloric content, with carbohydrates assigned a value of 50% of calories and protein assigned a value of 20% of calories. Carbohydrates should be obtained primarily from foods with a low to medium glycemic index, and simple sugars (monosaccharides, disaccharides) should be strictly limited. Patients are encouraged to choose healthy fats (monounsaturated and polyunsaturated fats). The duration of the study is 2 months.

At the end of the study, participants will be divided into tertiles based on the percentage of weight loss during the two-month period. Subsequent comparisons of study outcomes will be made between tertile 1 and tertile 3.

Venous blood samples will be collected from all patients following an overnight fast in to heparinized tubes. Following the centrifugation of the whole blood sample, the plasma is initially separated and subsequently frozen until the test is conducted. Additionally, the buffy coat, which contains leukocytes and is delineated by the interface between plasma at the superior aspect and red blood cells at the inferior aspect, is separated. Subsequent to this separation, the RNA Later solution is added to the buffy coat, which is then stored in a freezer. Total RNA will be extracted from isolated white blood cells using Trizol, and cDNA will be synthesized from these samples. Subsequently, the relative expression levels of the leptin receptor and SIRT-1 genes are determined through the use of specific primers and SYBR green master mix and Step-one plus system. The plasma sample is analyzed to measure several key parameters, including the lipid profile, insulin, leptin, adiponectin, C-reactive protein, and interleukin-6, by using commercial kits. The data will undergo analysis using SPSS software.

Being tested
Low-calorie diet
Medical subject headings
Obesity, Overweight, Hypertriglyceridemia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Low-calorie dietOther

    Low-calorie diet based on calculated calorie needs

Study groups in NCT07012226
Study groupRoleWhat they receive
Low-calorie dietOtherLow-calorie diet
Receives: Other: Low-calorie diet

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Gene expression of SIRT1

    Expression levels of SIRT1 gene in white blood cells

    Measured: up to 2 months

  2. Plasma lipid profile

    The plasma concentrations of triglycerides, cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol

    Measured: up to 2 months

Secondary outcomes (3)
  1. Plasma adipokines

    Plasma concentrations of adiponectin, leptin, and insulin.

    Measured: up to 2 months

  2. Gene expression of leptin receptor

    Gene expression of the leptin receptor in leukocytes

    Measured: up to 2 months

  3. Plasma inflammatory markers

    Plasma concentrations of the inflammatory markers C-reactive protein and interleukin-6

    Measured: up to 2 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Jun 2025
  2. Study start10 Jun 2025
  3. Primary completion12 Jan 2026
  4. Study completion27 Jan 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07012226
Sponsor's protocol ID
43014022
Status last verified
May 2025
First submitted
27 May 2025
Last updated
28 Jan 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: I do not have access to a reputable external site to share IPD information.

Questions about this trial

What is this clinical trial studying?

A study testing Low-calorie diet in people with Obesity and Overweight and Hypertriglyceridaemia, run by Shahid Beheshti University of Medical Sciences at 1 site in Iran.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Iran. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Gene expression of SIRT1 (time frame: up to 2 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in